Introduction: Depression is a widespread mental illness that affects a large portion of the world population and many of those who suffer from depression are resistant to treatment currently available. The purpose of this review is to compare the efficacy of psilocybin to the current available methods for the treatment of refractory depression. Methods: PubM...
Objective Despite many decades of experimental studies and clinical trials involving a variety of psychedelic agents, we still lack a comprehensive understanding of the effects of these substances on psychological experiences. As such, we designed and conducted a study to comprehensively characterise the effects of both psilocybin and 3,4-Methylenedioxymetha...
The medical utility of psychedelics has been the subject of significant scientific interest in recent years. While most of these substances remain Schedule I under the Controlled Substances Act, advancements in research have led states to consider expanding legal access, impacting primary care, where patients often seek mental health support and treatment. I...
This study presents a scientometric analysis of the scientific literature on the clinical use of psilocybin in mental disorders, covering publications from 2023 to 2025. The objective is to identify research trends, collaboration networks, and the scientific impact of this rapidly evolving field. A total of 359 unique records were retrieved from Scopus and W...
Abstract Background and aims Interest in psychedelic research has grown significantly in recent years and the naturally derived substance psilocybin, in combination with therapy, has shown promising results as a treatment for a range of psychiatric conditions. However, the negative effects and risks of psilocybin-assisted treatment are not well-established. ...
Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps remain regarding (1) psilocybin's general mode of action and (2) AUD-specific alterations of responsivity...
Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychede...
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts Offer Tips on Talking With Patients About PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.51AbstractPsychedelics differ from one another in their mechanism of action and po...
Back to table of contents Previous article Next article Annual MeetingFull AccessPsychedelic Therapy Requires Enhanced Consent DiscussionsNick ZagorskiNick ZagorskiPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.46AbstractThe presenters at an Annual Meeting session cautioned that patients pursuing psychedelic-assisted psychotherapy will...
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts to Discuss the Ethics of PsychedelicsTerri D'ArrigoTerri D'ArrigoPublished Online:27 Mar 2023https://doi.org/10.1176/appi.pn.2023.04.3.10AbstractA session at APA's Annual Meeting will cover the current state of psychedelics research and offer points to consider in the ev...
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsychedelic Therapy Hits Another Milestone, But Caution UrgedNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:22 Jul 2021https://doi.org/10.1176/appi.pn.2021.7.14AbstractPositive findings from a phase 3 trial may have brought MDMA-assisted the...
Recently, we presented a strategy for analysis of eight biomarkers in human urine to verify toxic mushroom or Ricinus communis ingestions. However, screening for the full panel is not always necessary. Thus, we aimed to develop a strategy to reduce analysis time and by focusing on two sets of analytes. One set (A) for biomarkers of late-onset syndromes, such...
Back to table of contents Previous article Next article APA & MeetingsFull AccessSession on Psychedelics Sure to Be EnlighteningNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:2 Mar 2021https://doi.org/10.1176/appi.pn.2021.3.14AbstractLeaders in psychedelic research will discuss the therapeutic potential of psychedelic compoun...
Psilocin is a molecule found in psilocybin mushrooms, which are typically consumed recreationally for their hallucinogenic effects. Recently, studies have shown that psilocin can have almost immediate antidepressant effects in patients who are treatment-resistant to medications that increase serotonin levels in the synapse. Researchers believe that the molec...
The analytical proof of a toxic mushroom and/or plant ingestion at an early stage of a suspected intoxication can be crucial for fast therapeutic decision making. Therefore, comprehensive analytical procedures need to be available. This study aimed to develop a strategy for the qualitative analysis of α- and β-amanitin, psilocin, bufotenine, muscarine, musci...
